Cancer drug delay unacceptable

The New Zealand Herald: "A drug credited with saving lives is facing unacceptable delays for public funding, say a cancer specialist. Mabthera, one of a new generation of smart drugs like Herceptin that targets specific characteristics of cancer cells, is already funded for an aggressive form of lymphoma."